RU2013110844A - АНТИТЕЛА ПРОТИВ IL-1β И IL-18, ИСПОЛЬЗУЕМЫЕ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ - Google Patents
АНТИТЕЛА ПРОТИВ IL-1β И IL-18, ИСПОЛЬЗУЕМЫЕ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ Download PDFInfo
- Publication number
- RU2013110844A RU2013110844A RU2013110844/10A RU2013110844A RU2013110844A RU 2013110844 A RU2013110844 A RU 2013110844A RU 2013110844/10 A RU2013110844/10 A RU 2013110844/10A RU 2013110844 A RU2013110844 A RU 2013110844A RU 2013110844 A RU2013110844 A RU 2013110844A
- Authority
- RU
- Russia
- Prior art keywords
- antibody
- disease
- specified
- binds
- antibodies
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title claims abstract 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract 27
- 238000000034 method Methods 0.000 claims abstract 40
- 230000000694 effects Effects 0.000 claims abstract 5
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract 2
- 208000011594 Autoinflammatory disease Diseases 0.000 claims abstract 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims abstract 2
- 208000026278 immune system disease Diseases 0.000 claims abstract 2
- 208000027866 inflammatory disease Diseases 0.000 claims abstract 2
- 230000002757 inflammatory effect Effects 0.000 claims abstract 2
- 208000002780 macular degeneration Diseases 0.000 claims abstract 2
- 230000001404 mediated effect Effects 0.000 claims abstract 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 4
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 230000000903 blocking effect Effects 0.000 claims 2
- 230000003472 neutralizing effect Effects 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 230000009977 dual effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 108010034143 Inflammasomes Proteins 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37376010P | 2010-08-13 | 2010-08-13 | |
| US61/373,760 | 2010-08-13 | ||
| PCT/US2011/047532 WO2012021773A1 (en) | 2010-08-13 | 2011-08-12 | Antibodies to il-1beta and il-18, for treatment of disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2013110844A true RU2013110844A (ru) | 2014-09-20 |
Family
ID=44511598
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013110844/10A RU2013110844A (ru) | 2010-08-13 | 2011-08-12 | АНТИТЕЛА ПРОТИВ IL-1β И IL-18, ИСПОЛЬЗУЕМЫЕ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP2603525A1 (es) |
| JP (1) | JP2013537539A (es) |
| KR (1) | KR20130100125A (es) |
| CN (2) | CN103154032A (es) |
| BR (1) | BR112013003279A2 (es) |
| CA (1) | CA2808185A1 (es) |
| MX (1) | MX2013001267A (es) |
| RU (1) | RU2013110844A (es) |
| WO (1) | WO2012021773A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9707235B1 (en) * | 2012-01-13 | 2017-07-18 | University Of Kentucky Research Foundation | Protection of cells from degeneration and treatment of geographic atrophy |
| HUE052342T2 (hu) | 2013-03-14 | 2021-04-28 | Univ Laval | Elektroretinográfia (ERG) használata a pszichiátriai rendellenességek értékelésére |
| MX2015015784A (es) * | 2013-05-17 | 2016-03-11 | Genentech Inc | Metodos para diagnosticar y tratar enfermedad inflamatoria de intestino. |
| CN103554264B (zh) * | 2013-11-05 | 2015-08-12 | 哈尔滨博翱生物医药技术开发有限公司 | 针对IL-1β和IL-17A的双特异性抗体及其应用 |
| JP6787888B2 (ja) * | 2014-11-10 | 2020-11-18 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 抗ｉｌ−１ベータ抗体及び使用方法 |
| AU2015345323A1 (en) | 2014-11-10 | 2017-04-06 | F. Hoffmann-La Roche Ag | Bispecific antibodies and methods of use in ophthalmology |
| MX2017005642A (es) | 2014-11-10 | 2017-07-24 | Hoffmann La Roche | Anticuerpos anti-angiopoyetina 2 (ang2) y metodos de uso. |
| GB201815045D0 (en) * | 2018-09-14 | 2018-10-31 | Univ Ulster | Bispecific antibody targeting IL-1R1 and NLPR3 |
| CN110251657B (zh) * | 2019-06-14 | 2020-11-17 | 中山大学 | Ebv brlf1及其功能性小肽在抑制炎症小体活性中的应用 |
| CA3173341A1 (en) | 2020-03-26 | 2021-09-30 | Diamentis Inc. | Systems and methods for processing retinal signal data and identifying conditions |
| US12441786B2 (en) | 2020-11-18 | 2025-10-14 | Novartis Ag | Bispecific antibodies for use in treatment of NLRC4-GOF inflammasomapathy |
| CA3219360A1 (en) * | 2021-06-22 | 2022-12-29 | Novartis Ag | Bispecific antibodies for use in treatment of hidradenitis suppurativa |
| KR20240141832A (ko) | 2022-02-09 | 2024-09-27 | 다이아멘티스 인크. | 망막 자극 및/또는 망막 신호 데이터를 수집하기 위한 시스템 및 방법 |
Family Cites Families (107)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US577300A (en) | 1897-02-16 | Printing-press | ||
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4010989A (en) | 1975-10-14 | 1977-03-08 | American Hospital Supply Corporation | Lockable drawer compartment |
| USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
| US4515893A (en) | 1979-04-26 | 1985-05-07 | Ortho Pharmaceutical Corporation | Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells |
| US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
| NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
| US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
| US5672347A (en) | 1984-07-05 | 1997-09-30 | Genentech, Inc. | Tumor necrosis factor antagonists and their use |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| SE8505922D0 (sv) | 1985-12-13 | 1985-12-13 | Kabigen Ab | Construction of an igg binding protein to facilitate downstream processing using protein engineering |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| IL87737A (en) | 1987-09-11 | 1993-08-18 | Genentech Inc | Method for culturing polypeptide factor dependent vertebrate recombinant cells |
| US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
| US5770701A (en) | 1987-10-30 | 1998-06-23 | American Cyanamid Company | Process for preparing targeted forms of methyltrithio antitumor agents |
| US5091313A (en) | 1988-08-05 | 1992-02-25 | Tanox Biosystems, Inc. | Antigenic epitopes of IgE present on B cell but not basophil surface |
| US5720937A (en) | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
| DE68919361T2 (de) | 1988-06-21 | 1995-05-24 | Genentech Inc | Therapeutische zusammensetzungen für die behandlung von myocard-infarkten. |
| WO1990003430A1 (en) | 1988-09-23 | 1990-04-05 | Cetus Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| WO1991000360A1 (en) | 1989-06-29 | 1991-01-10 | Medarex, Inc. | Bispecific reagents for aids therapy |
| CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| WO1992000373A1 (en) | 1990-06-29 | 1992-01-09 | Biosource Genetics Corporation | Melanin production by transformed microorganisms |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| DE122004000008I1 (de) | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
| EP0602126B1 (en) | 1991-08-14 | 2003-03-05 | Genentech, Inc. | Immunoglobulin variants for specific fc epsilon receptors |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| WO1994004690A1 (en) | 1992-08-17 | 1994-03-03 | Genentech, Inc. | Bispecific immunoadhesins |
| DE69315847T2 (de) | 1992-08-21 | 1998-06-25 | Genentech Inc | Verfahren zur behandlung einer durch lfa-1 vermittelten störung |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| PL174494B1 (pl) | 1992-11-13 | 1998-08-31 | Idec Pharma Corp | Kompozycja farmaceutyczna do leczenia chłoniaka z limfocytów B i sposób wytwarzania kompozycji farmaceutycznej do leczenia chłoniaka z limfocytów B |
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| DK0733207T3 (da) | 1993-12-10 | 1998-04-20 | Genentech Inc | Fremgangsmåder til diagnose af allergi og screening af anti-allergi-terapeutika |
| SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
| EP0739214B1 (en) | 1994-01-18 | 1998-03-18 | Genentech, Inc. | A METHOD OF TREATMENT OF PARASITIC INFECTION USING IgE ANTAGONISTS |
| US5686070A (en) | 1994-03-03 | 1997-11-11 | Genentech, Inc. | Methods for treating bacterial pneumonia |
| US5856179A (en) | 1994-03-10 | 1999-01-05 | Genentech, Inc. | Polypeptide production in animal cell culture |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
| JPH11507535A (ja) | 1995-06-07 | 1999-07-06 | イムクローン システムズ インコーポレイテッド | 腫瘍の成長を抑制する抗体および抗体フラグメント類 |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| WO1997026912A2 (en) | 1996-01-23 | 1997-07-31 | Genentech, Inc. | Anti-cd18 antibodies for use against stroke |
| US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
| ATE267257T1 (de) | 1996-11-27 | 2004-06-15 | Genentech Inc | Humanisierte anti-koerper gegen cd11a |
| JP3957765B2 (ja) | 1997-04-07 | 2007-08-15 | ジェネンテク・インコーポレイテッド | 抗ｖｅｇｆ抗体 |
| JP4213224B2 (ja) | 1997-05-02 | 2009-01-21 | ジェネンテック，インコーポレーテッド | ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法 |
| EP1860187B1 (en) | 1997-05-15 | 2011-07-13 | Genentech, Inc. | Apo-2 receptor |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
| EP1034298B1 (en) | 1997-12-05 | 2011-11-02 | The Scripps Research Institute | Humanization of murine antibody |
| ATE348163T1 (de) | 1998-10-23 | 2007-01-15 | Amgen Inc | Thrombopoietin substitute |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
| BR0015224A (pt) | 1999-10-29 | 2002-07-09 | Genentech Inc | Anticorpo anti-antìgeno de célula estaminal prostática (psca) isolado, anticorpo monoclonal anti-psca, ácido nucleico isolado, vetor de expressão, célula, célula hospedeira, método de produção de anticorpo, composição método in vitro para matar uma célula cancerosa que expresse psca, uso de uma anticorpo monoclonal anti-psca e artigo industrializado |
| WO2001049698A1 (en) | 1999-12-29 | 2001-07-12 | Immunogen, Inc. | Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use |
| CN101062415A (zh) * | 2000-02-21 | 2007-10-31 | 应用研究系统Ars股份公司 | Il－18抑制剂的应用 |
| EP2857516B1 (en) | 2000-04-11 | 2017-06-14 | Genentech, Inc. | Multivalent antibodies and uses therefor |
| CA2411374C (en) * | 2000-06-29 | 2012-10-30 | Abbott Laboratories | Dual specificity antibodies and methods of making and using |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| ES2295228T3 (es) | 2000-11-30 | 2008-04-16 | Medarex, Inc. | Roedores transcromosomicos transgenicos para la preparacion de anticuerpos humanos. |
| EP1345967B1 (en) | 2000-12-22 | 2011-08-10 | Grad, Carole, Legal representative of Kaplan, Howard | Phage display libraries of human v h fragments |
| CN1970077A (zh) | 2001-05-11 | 2007-05-30 | 安姆根有限公司 | 与tall－1结合的肽和相关分子 |
| US7205275B2 (en) | 2001-10-11 | 2007-04-17 | Amgen Inc. | Methods of treatment using specific binding agents of human angiopoietin-2 |
| US7332474B2 (en) | 2001-10-11 | 2008-02-19 | Amgen Inc. | Peptides and related compounds having thrombopoietic activity |
| US7138370B2 (en) | 2001-10-11 | 2006-11-21 | Amgen Inc. | Specific binding agents of human angiopoietin-2 |
| JP2005289809A (ja) | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | 突然変異重鎖抗体 |
| US6919426B2 (en) | 2002-09-19 | 2005-07-19 | Amgen Inc. | Peptides and related molecules that modulate nerve growth factor activity |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| CA2529819A1 (en) | 2003-06-30 | 2004-09-23 | Domantis Limited | Pegylated single domain antibodies |
| BR122018071808B8 (pt) | 2003-11-06 | 2020-06-30 | Seattle Genetics Inc | conjugado |
| ZA200608130B (en) | 2004-03-31 | 2008-12-31 | Genentech Inc | Humanized anti-TGF-beta antibodies |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| RU2515108C2 (ru) | 2005-08-19 | 2014-05-10 | Эббви Инк | Иммуноглобулин с двойными вариабельными доменами и его применения |
| US20090298764A1 (en) * | 2006-03-15 | 2009-12-03 | Regents Of The University Of Colorado | Gene and pathway and their use in methods and compositions for predicting onset or progression of autoimmune and/or autoinflammatory diseases |
| RU2008144802A (ru) * | 2006-04-14 | 2010-05-20 | Новартис АГ (CH) | Применение антител против ил-1 для лечения глазных расстройств |
| PL2059533T3 (pl) | 2006-08-30 | 2013-04-30 | Genentech Inc | Przeciwciała wieloswoiste |
| BRPI0812040A2 (pt) * | 2007-05-29 | 2014-10-21 | Novartis Ag | Indicações para terapia de anti-il-i-beta |
| EP2247310A4 (en) * | 2008-01-30 | 2012-06-27 | Abbott Lab | COMPOSITIONS AND METHODS FOR CRYSTALLIZING ANTIBODY FRAGMENTS |
| WO2010028273A1 (en) * | 2008-09-05 | 2010-03-11 | Xoma Technology Ltd. | Methods for improvement of beta cell function |
-
2011
- 2011-08-12 BR BR112013003279A patent/BR112013003279A2/pt not_active IP Right Cessation
- 2011-08-12 CA CA2808185A patent/CA2808185A1/en not_active Abandoned
- 2011-08-12 RU RU2013110844/10A patent/RU2013110844A/ru not_active Application Discontinuation
- 2011-08-12 CN CN2011800493677A patent/CN103154032A/zh active Pending
- 2011-08-12 WO PCT/US2011/047532 patent/WO2012021773A1/en not_active Ceased
- 2011-08-12 MX MX2013001267A patent/MX2013001267A/es not_active Application Discontinuation
- 2011-08-12 EP EP11748847.8A patent/EP2603525A1/en not_active Withdrawn
- 2011-08-12 CN CN201410753624.0A patent/CN104474546A/zh active Pending
- 2011-08-12 JP JP2013524239A patent/JP2013537539A/ja active Pending
- 2011-08-12 KR KR1020137006238A patent/KR20130100125A/ko not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CN103154032A (zh) | 2013-06-12 |
| WO2012021773A1 (en) | 2012-02-16 |
| CN104474546A (zh) | 2015-04-01 |
| CA2808185A1 (en) | 2012-02-16 |
| MX2013001267A (es) | 2013-04-10 |
| JP2013537539A (ja) | 2013-10-03 |
| KR20130100125A (ko) | 2013-09-09 |
| EP2603525A1 (en) | 2013-06-19 |
| BR112013003279A2 (pt) | 2016-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013110844A (ru) | АНТИТЕЛА ПРОТИВ IL-1β И IL-18, ИСПОЛЬЗУЕМЫЕ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ | |
| RU2017137010A (ru) | Анти-сеасам6 антитела и их применения | |
| JP2014509510A5 (es) | ||
| RU2012119788A (ru) | Связывающие il-1 белки | |
| PE20200862A1 (es) | Anticuerpos anti-trem2 y metodos relacionados | |
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| HRP20170568T1 (hr) | Protutijela anti-ox40 i postupci za njihovu uporabu | |
| RU2019118359A (ru) | Антитело к cd73 человека | |
| EA201370105A1 (ru) | Человеческие антитела против человеческого tnf-подобного лиганда-1а (tl1a) | |
| CN103172738A (zh) | Il-12/p40结合蛋白 | |
| RU2017127772A (ru) | Человеческие антитела к токсинам clostridium difficile | |
| CN101512008A (zh) | 白介素-13结合蛋白 | |
| RU2015121755A (ru) | Антагонисты ил-6 и их применение | |
| JP2014534239A5 (es) | ||
| JP2014511179A5 (es) | ||
| NZ610734A (en) | Human antibodies to the glucagon receptor | |
| NZ629178A (en) | Antibodies to matrix metalloproteinase 9 | |
| EA201490020A1 (ru) | Растворимые белки для применения в качестве терапевтических средств | |
| RU2014148502A (ru) | Человеческие антитела к fel d1 и способы их применения | |
| JP2015533795A5 (es) | ||
| NZ602892A (en) | Antibodies that bind human cd27 and uses thereof | |
| JP2016509585A5 (es) | ||
| JP2015509962A5 (es) | ||
| JP2013537539A5 (es) | ||
| RU2015118180A (ru) | Антитела к бета-амилоиду |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20160407 |